Hematology Xagena

Xagena Mappa
Xagena Newsletter

Blinatumomab: positive results in patients with relapsed / refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia

Results of a phase 2 open-label, single-arm, multicenter trial to evaluate the efficacy and safety of Blinatumomab ( Blincyto ) in adults with relapsed or refractory Philadelphia chromosome-positive ( Ph+ ) B-cell precursor acute lymphoblastic leukemia ( ALL ) were presented.
The investigational study showed Blinatumomab monotherapy induced a complete remission or complete remission with partial hematological recovery within two cycles of treatment in a clinically meaningful number of patients.
Overall safety results from this study were consistent with the known Blinatumomab safety profile.

Approximately one-fourth of adult ALL expresses the oncogenic protein BCR-ABL1 that results from the t (9;22) chromosome translocation known as the Philadelphia chromosome.

This study enrolled adult subjects with relapsed or refractory Ph+ B-cell precursor acute lymphoblastic leukemia. This was an open-label, single-arm, multicenter study consisting of a screening period, an induction treatment period ( two cycles of Blinatumomab ), a consolidation treatment period ( up to three additional cycles of Blinatumomab for applicable subjects ), and a safety follow-up visit 30 days after treatment.

Following the safety follow-up visit, subjects were followed for response duration and survival every 3 months for 18 months or death, whichever occurred first.

Blinatumomab is the first bispecific CD19-directed CD3 T cell engager ( BiTE ) antibody construct product, and the first single-agent immunotherapy to be approved by the FDA ( Food and Drug Administration ) for the treatment of patients with Philadelphia chromosome-negative ( Ph- ) relapsed or refractory B-cell precursor acute lymphoblastic leukemia, a rare and rapidly progressing cancer of the blood and bone marrow.
Prior to approval, Blincyto was granted breakthrough therapy and priority review designations by the FDA.
Blincyto has a BOXED WARNING in its product label regarding cytokine release syndrome ( CRS ) and neurological toxicities.

Bispecific T cell engager ( BiTE ) antibody constructs are a type of immunotherapy being investigated for fighting cancer by helping the body's immune system to detect and target malignant cells. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells to cancer cells.
BiTE antibody constructs help place the T cells within reach of the targeted cell, with the intent of allowing T cells to inject toxins and trigger the cancer cell to die ( apoptosis ). ( Xagena )

Source: Amgen, 2015